person
Filip B.
- Country
- Belgium
- Department
- Maag-Darm-Leverziekten
Research Overview
assignment
24
Clinical Trials ·
- A randomized, double-blind, multicenter phase III study to evaluate the long-term efficacy and safety of ABX464 25 mg or 50 mg once daily as a maintenance therapy in subjects with moderately to severely active ulcerative colitis
- Efficacy and Safety of Obefazimod (ABX464) in Adults with Moderately to Severely Active Ulcerative Colitis: A Randomized Placebo‑Controlled Phase III Study
- Phase 3b, Randomized, Open‑Label, Active‑Controlled Trial Comparing Guselkumab Versus Risankizumab for Efficacy and Safety in Moderately to Severely Active Crohn’s Disease
location_city
1
Research Sites
Data & Insights
medical_services
Primary Speciality
Main therapeutic area
handshake
Return Partnerships
Recurring site collaborations
332
Sites with multiple studies
Has run more than one trial at 332 of 535 partner sites.
Specializations
Inflammatory Bowel Disease Management
Specializes in treating moderately to severely active ulcerative colitis and Crohn's disease, with particular focus on innovative therapeutic approaches and long-term disease management strategies.
- Novel Therapeutic Agents
- Long-term Disease Control
- Treatment Response Monitoring
Post-Surgical Care
Focuses on post-operative disease management in Crohn's disease patients, particularly studying recurrence prevention and therapeutic optimization after intestinal resection.
- Surgical Outcome Assessment
- Recurrence Prevention
- Post-operative Monitoring
Hepatic Oncology
Conducts research in hepatocellular carcinoma treatment, investigating advanced therapeutic approaches for both early-stage and metastatic disease.
- Cancer Recurrence Prevention
- Advanced Stage Treatment
- Combination Therapy Approaches
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.